Analyst Price Targets — JBIO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 6, 2026 5:15 pm | Alex Thompson | Stifel Nicolaus | $40.00 | $14.07 | StreetInsider | Jade Biosciences (JBIO) PT Raised to $40 at Stifel: "We like the setup for JADE101" |
| January 7, 2026 11:07 am | — | H.C. Wainwright | $25.00 | $13.17 | TheFly | Jade Biosciences initiated with a Buy at H.C. Wainwright |
| October 9, 2025 10:22 am | — | BTIG | $28.00 | $9.08 | TheFly | Jade Biosciences initiated with a Buy at BTIG |
| June 16, 2025 12:17 am | Vamil Divan | Guggenheim | $14.00 | $6.76 | TheFly | Jade Biosciences upgraded to Buy from Neutral at Guggenheim |
| May 5, 2025 8:28 am | Alex Thompson | Stifel Nicolaus | $19.00 | $11.50 | TheFly | Jade Biosciences initiated with a Buy at Stifel |
Latest News for JBIO
SAN FRANCISCO and VANCOUVER, British Columbia, March 06, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced financial results for the fourth quarter and full year ending December 31, 2025, and provided a corporate update.
Jade Biosciences, Inc. (JBIO) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Prepared Remarks Transcript
SAN FRANCISCO and VANCOUVER, British Columbia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcoming conferences:
Jade Biosciences, Inc. (JBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
JADE101 Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected in the first half of 2026 Phase 2 clinical trial of JADE101 in patients with IgA nephropathy expected to begin mid-2026; preliminary data anticipated in 2027 JADE201, a half-life extended afucosylated anti-BAFF receptor antibody, expected to advance into first-in-human study in rheumatoid arthritis patients in the second quarter…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for JBIO.
U.S. House Trading
No House trades found for JBIO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.